Datapoint

Datapoint: Keytruda Scores First-Line Esophageal Cancer Nod

The FDA last week approved Merck & Co.’s Keytruda for the treatment of newly diagnosed esophageal or gastroesophageal junction carcinoma in tandem with chemotherapy. Keytruda is the first PD-1/L1 agent to be...
0 Comments

Datapoint: Hawaii Announces New Medicaid Contract Awards

After a year-long delay spurred by the COVID-19 pandemic, Hawaii last week awarded new state Medicaid contracts for its managed care program, MEDQUEST. All of the selected MCOs are incumbents. AlohaCare, Hawaii Me...
0 Comments

Datapoint: Biden Admin Nixes Work Requirements in Two States

The Biden administration last week quietly rescinded Medicaid work requirement approvals in Arkansas and New Hampshire, according to letters sent by CMS to the states. The U.S. Supreme Court was supposed to hear ...
0 Comments

Datapoint: J&J’s Ponvory to Enter MS Market

The FDA last week approved Johnson & Johnson’s Janssen unit’s Ponvory for the treatment of relapsing forms of multiple sclerosis (MS). The SIP modulator will face off against Novartis stalwarts Gilenya and...
0 Comments

Datapoint: Ohio Sues Centene for Medicaid ‘Scheme’

Ohio Attorney General Dave Yost (R) on March 11 revealed the state is suing Centene Corp. “for an elaborate scheme to maximize company profits at the expense of the Ohio Department of Medicaid.” The state ...
0 Comments

Datapoint: Fotivda Scores Kidney Cancer Nod

The FDA last week approved Aveo Oncology’s Fotivda as a third-line treatment for kidney cancer, following years of regulatory hurdles. Pfizer’s Sutent is one of the most advantaged drugs in the kidney cancer s...
0 Comments

Datapoint: Cigna Aims for 25% Commercial Health Plan Growth by 2025

Cigna Corp. aims to grow its commercial health plan business by 25% by 2025, according to a March 8 presentation to investors. The insurer is focused on Medicare Advantage (MA), noting that 150,000 of its comm...
0 Comments

Datapoint: Clover Health Reports First Year of Earnings as a Public Company

In its first earnings report released as a publicly traded company, Medicare Advantage (MA) startup Clover Health on March 1 said it generated more than $670 million in revenue for the full year ending Dec. 31, ...
0 Comments

Datapoint: Yescarta Scores Follicular Lymphoma Nod

The FDA on March 5 approved Gilead Sciences’ Yescarta for the treatment of relapsed or refractory follicular lymphoma in patients that have not responded to at least two prior treatments, a feat unmatched by its...
0 Comments

Datapoint: 2021 Medicare Advantage AEP Results

Medicare Advantage enrollment grew 9.9%, to 26.3 million lives, from February 2020 to February 2021, signs of another strong annual enrollment period. Market leader UnitedHealthcare saw a 13.5% increase, to 7....
0 Comments